Navigation Links
Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting

CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013 /PRNewswire/ --

Biovista and the CFIDS Association of America announced today the successful completion of the first phase of their collaboration. Funded as part of the CFIDS' Research Institute Without Walls, Biovista identified candidate treatments for CFS using its state-of-the-art COSS approach. Two candidate treatments, including a combination therapy, were identified and are being prepared for proof-of-concept clinical trials, with an FDA pre-IND meeting scheduled in Q3 2013.

"We are very excited to have reached this stage within a year of starting our collaboration. We look forward to furthering our understanding of this complex disease and developing a treatment that will improve CFS patients' quality of life," said Dr. Andreas Persidis , Biovista's CEO. "Our work is an example of things to come in terms of novel collaboration models that promise to accelerate treatment development and, through the drug repositioning approach, do so cost effectively," Dr Persidis added.

"There is a big gap in the pipeline that moves basic laboratory research into safe and effective treatments. Without a bridge to bring discoveries to the clinic, laboratory research rarely becomes more than a paper. We are providing the means for basic researchers to move discoveries through the translational research pipeline with our Research Institute Without Walls," said Kim McCleary , president and CEO of CFIDS.

"Therapies for ME/CFS are an unmet medical need. This is largely due to the lack of translating the scientific knowledge into meaningful impact for patients," added Dr. Suzanne D. Vernon , Scientific Director of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill this gap. Biovista recognized the opportunity for discovery. This drug repositioning project is an excellent example of effective use of existing information to make a new treatment discovery."

About Biovista

Biovista finds novel uses for existing drugs and profiles their side effects using mechanism of action analysis. Biovista develops its own pipeline in CNS, oncology, auto-immune and rare diseases and collaborates with biopharmaceutical companies and Patient Groups on indication expansion, portfolio de-risking, and adverse event prediction. (


The CFIDS Association of America is at the leading edge of ME/CFS research. For more information, please visit The Association's web site at or their research blog at

Dr. Andreas Persidis
T: +1-434-242-6514
The CFIDS Association of America
Dr. Suzanne D. Vernon

SOURCE Biovista
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
3. Washington State Medical Association (WSMA) Urges Adults to Get Recommended Immunizations
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. Attack on the Website of the American Pharmacists Association
10. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):